Nureca Ltd closes DRI customs case with ₹57.13 lakh appropriation
- DRI proceedings against Nureca Ltd closed regarding product classification
- Pre-deposit of ₹57.13 lakh appropriated as differential duty and interest
- Liabilities discharged through appropriation, ending the regulatory matter

*this image is generated using AI for illustrative purposes only.
Nureca Limited has received closure of customs proceedings from the Directorate of Revenue Intelligence (DRI) following the appropriation of a pre-deposit amounting to ₹57.13 lakh.
The matter concerned product classification under Section 108 of the Customs Act, 1962. The Commissioner of Customs (NS-V) determined that the initial deposit covered differential duty and applicable interest for imports under relevant Bills of Entry.
Resolution of Regulatory Matter
This development follows an earlier intimation dated May 24, 2026, where Nureca disclosed receipt of a hearing notice from the DRI. The company had subsequently made a pre-deposit of INR 57,12,811 to address the potential liability.
With the recent order, the liabilities arising from the specific imports have been discharged through this appropriation. Consequently, the regulatory matter stands closed without further penalty or extended litigation.
What the Numbers Show
The resolution confirms that the financial impact was limited to the ₹57.13 lakh already provisioned or paid as a pre-deposit. By treating this amount as duty and interest rather than a penalty, the company avoided additional cash outflows beyond the initially estimated liability range.
Historical Stock Returns for Nureca
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.36% | -3.17% | -0.42% | +22.65% | +35.03% | 0.0% |
Will this resolution influence Nureca's future import compliance protocols or product classification strategies to mitigate similar regulatory risks?
How might the closure of these customs proceedings impact investor sentiment and Nureca's share price volatility in the short term?
Does this outcome set a precedent for other pharmaceutical companies facing similar Section 108 classification disputes with the DRI?


































